ItalyItaly

Italian cancer researchers demonstrate efficacy of radioactive microspheres against liver metastases

23.08.2010

Rome/Sydney – A novel therapy based on Yttrium-90-loaded beads has been shown to be safe and effective in patients with inoperable colorectal cancer liver metastases (British Journal of Cancer 103: 324-331) in a phase II trial with 52 patients. As the study group, headed by Prof. Maurizio Cosimelli at the National Cancer Institute Regina Elena in Rome, demonstrated that liver tumours in one patient (2%) disappeared and that 11 patients (22%) showed a partial response – their tumours shrank by at least 30%. Additionally, a further 12 patients (24%) showed stabilisation of their disease. Liver tumours shrank in two patients (4%) far enough to make a potentially curative surgery can. The overall median survival was 12.6 months for all patients participating in the experiment. The cancer experts recorded a significantly longer survival in 24 patients (48%) responding to the SIR-spheres (Sirtex Medical Pty. Sydney) or where the disease was stabilized in comparison to patients as non-responsive (median 16 months versus 8 months, P = 0.0006). Furthermore, 40% of those who responded were still alive two years after treatment, compared to none of those subjects who did not respond. Light to moderate side effects, especially fever and pain appeared in 16% of patients in the first 48 hours and at 22% between the third and 30 Days reported. The study was conducted as a single-arm study, as this group of patients had no other treatment options. Each year 145 000 Americans and 307,000 Europeans are diagnosed with colorectal cancer. About half of these patients develop metastases, mainly in the liver. Up to 90% of them die from liver failure. Selective Internal Radiation Therapy (SIRT) with the use of yttrium-90 resin beads loaded is a new approach for treating liver metastases. The microspheres are implanted by interventional radiologists to selectively targeted tumours with radiation, while the vital healthy liver tissue is spared and preserved.

ItalyItaly

07.03.2012

Toscana Biomarkers S.r.l has entered the market for biomarkers with its first diagnostic kit. In late January, the company from Siena signed a licence agreement with DIESSE Ricerche S.r.l, based in Genoa. DIESSE will produce and...

ItalyItaly

07.03.2012

Italian researchers have reprogrammed neonatal cardiomyocytes into iPSCs that can re-differentiate toward CMs more efficiently than either cardiac fibroblast-derived iPS cells or even ES cells. (Cell Death Differ.,...

ItalyItaly

09.01.2012

Rome – A cold virus isolated from chimpanzees might work as an vector for human vaccines. Adenoviruses are principally suitable as vectors for vaccines for their ability to induce strong immune responses. But as most humans have...

ItalyItaly

16.12.2011

Milan/Turku – Italian drug developer Newron SpA has had a roller-coaster ride in the last few months. First Merck Serono decided to drop its stake in the company’s Parkinson’s Disease candidate salfinamide, and returned the...

ItalyItaly

15.12.2011

Genoa/Irvine – Researchers from the universities at Genoa and Irvine (US) have patented a new compound that blocks removal of the endo­cannabinoid painkiller anandamide from the synaptic space by a selective transport system....

ItalyItaly

01.10.2011

Parma/Baranzate – Chiesi Farmaceutici Spa has said it will lengthen its long-term collaboration with NiKem Research, which is focused on developing treatments within the respiratory therapeutic area. The two drug developers have...

ItalyItaly

01.10.2011

Milan/Turku – Biotie Therapies ASA’s announcement that it had signed an agreement to acquire Newron Pharma­ceuticals S.p.A. for €45m is both good and bad news for the Italian biotechnology sector. While Italy is losing one of its...

ItalyItaly

19.08.2011

Como – Shares in Gentium SpA lost about a third of their value on Thursday after The Italian biopharmaceutical company withdrew a marketing application for its drug Defibrotide being used against complications related to stem...

ItalyItaly

01.08.2011

Milan/London – Italy’s MolMed SpA has signed a deal with UK-based pharmaceutical giant GlaxoSmithKline to develop a production process for a gene therapy against the rare ‘bubble boy disease’. Over the next two years, GSK will...

Displaying results 1 to 10 out of 181

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-italy/article/italian-cancer-researchers-demonstrate-efficacy-of-radioactive-microspheres-against-liver-metastases.html

Events

All Events

Stock list

All quotes

TOP

  • SANTHERA74.95 CHF10.30%
  • BIOTEST80.50 EUR6.83%
  • WILEX2.22 EUR5.71%

FLOP

  • 4SC1.20 EUR-6.25%
  • VITA 343.78 EUR-2.83%
  • EPIGENOMICS3.12 EUR-2.50%

TOP

  • MAGFORCE6.50 EUR20.4%
  • LONZA101.10 CHF9.2%
  • SANTHERA74.95 CHF7.8%

FLOP

  • WILEX2.22 EUR-32.3%
  • VITA 343.78 EUR-20.1%
  • MOLOGEN7.80 EUR-17.5%

TOP

  • SANTHERA74.95 CHF3556.1%
  • CO.DON2.50 EUR228.9%
  • PAION2.40 EUR185.7%

FLOP

  • CYTOS0.27 CHF-93.3%
  • MEDIGENE4.60 EUR-66.4%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 20.08.2014


Current issue

All issues

Product of the week

Products